453 related articles for article (PubMed ID: 18819002)
1. Validation of 70-gene prognosis signature in node-negative breast cancer.
Bueno-de-Mesquita JM; Linn SC; Keijzer R; Wesseling J; Nuyten DS; van Krimpen C; Meijers C; de Graaf PW; Bos MM; Hart AA; Rutgers EJ; Peterse JL; Halfwerk H; de Groot R; Pronk A; Floore AN; Glas AM; Van't Veer LJ; van de Vijver MJ
Breast Cancer Res Treat; 2009 Oct; 117(3):483-95. PubMed ID: 18819002
[TBL] [Abstract][Full Text] [Related]
2. Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature.
Mook S; Knauer M; Bueno-de-Mesquita JM; Retel VP; Wesseling J; Linn SC; Van't Veer LJ; Rutgers EJ
Ann Surg Oncol; 2010 May; 17(5):1406-13. PubMed ID: 20094918
[TBL] [Abstract][Full Text] [Related]
3. Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer.
Foekens JA; Atkins D; Zhang Y; Sweep FC; Harbeck N; Paradiso A; Cufer T; Sieuwerts AM; Talantov D; Span PN; Tjan-Heijnen VC; Zito AF; Specht K; Hoefler H; Golouh R; Schittulli F; Schmitt M; Beex LV; Klijn JG; Wang Y
J Clin Oncol; 2006 Apr; 24(11):1665-71. PubMed ID: 16505412
[TBL] [Abstract][Full Text] [Related]
4. A 38-gene expression signature to predict metastasis risk in node-positive breast cancer after systemic adjuvant chemotherapy: a genomic substudy of PACS01 clinical trial.
Jézéquel P; Campone M; Roché H; Gouraud W; Charbonnel C; Ricolleau G; Magrangeas F; Minvielle S; Genève J; Martin AL; Bataille R; Campion L
Breast Cancer Res Treat; 2009 Aug; 116(3):509-20. PubMed ID: 19020972
[TBL] [Abstract][Full Text] [Related]
5. Integrated gene expression profile predicts prognosis of breast cancer patients.
Li LF; Xu XJ; Zhao Y; Liu ZB; Shen ZZ; Jin WR; Shao ZM
Breast Cancer Res Treat; 2009 Jan; 113(2):231-7. PubMed ID: 18278552
[TBL] [Abstract][Full Text] [Related]
6. The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy.
Zhang Y; Sieuwerts AM; McGreevy M; Casey G; Cufer T; Paradiso A; Harbeck N; Span PN; Hicks DG; Crowe J; Tubbs RR; Budd GT; Lyons J; Sweep FC; Schmitt M; Schittulli F; Golouh R; Talantov D; Wang Y; Foekens JA
Breast Cancer Res Treat; 2009 Jul; 116(2):303-9. PubMed ID: 18821012
[TBL] [Abstract][Full Text] [Related]
7. Population-based molecular prognosis of breast cancer by transcriptional profiling.
Ma Y; Qian Y; Wei L; Abraham J; Shi X; Castranova V; Harner EJ; Flynn DC; Guo L
Clin Cancer Res; 2007 Apr; 13(7):2014-22. PubMed ID: 17404081
[TBL] [Abstract][Full Text] [Related]
8. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
Søiland H; Skaland I; Varhaug JE; Kørner H; Janssen EA; Gudlaugsson E; Baak JP; Søreide JA
Acta Oncol; 2009; 48(4):514-21. PubMed ID: 19107621
[TBL] [Abstract][Full Text] [Related]
9. Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients.
Sieuwerts AM; Look MP; Meijer-van Gelder ME; Timmermans M; Trapman AM; Garcia RR; Arnold M; Goedheer AJ; de Weerd V; Portengen H; Klijn JG; Foekens JA
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3319-28. PubMed ID: 16740753
[TBL] [Abstract][Full Text] [Related]
10. Prediction of breast cancer prognosis by gene expression profile of TP53 status.
Takahashi S; Moriya T; Ishida T; Shibata H; Sasano H; Ohuchi N; Ishioka C
Cancer Sci; 2008 Feb; 99(2):324-32. PubMed ID: 18271932
[TBL] [Abstract][Full Text] [Related]
11. Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer.
Urban P; Vuaroqueaux V; Labuhn M; Delorenzi M; Wirapati P; Wight E; Senn HJ; Benz C; Eppenberger U; Eppenberger-Castori S
J Clin Oncol; 2006 Sep; 24(26):4245-53. PubMed ID: 16963728
[TBL] [Abstract][Full Text] [Related]
12. DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients.
Nimmrich I; Sieuwerts AM; Meijer-van Gelder ME; Schwope I; Bolt-de Vries J; Harbeck N; Koenig T; Hartmann O; Kluth A; Dietrich D; Magdolen V; Portengen H; Look MP; Klijn JG; Lesche R; Schmitt M; Maier S; Foekens JA; Martens JW
Breast Cancer Res Treat; 2008 Oct; 111(3):429-37. PubMed ID: 17965955
[TBL] [Abstract][Full Text] [Related]
13. Minimal axillary lymph node involvement in breast cancer has different prognostic implications according to the staging procedure.
Montagna E; Viale G; Rotmensz N; Maisonneuve P; Galimberti V; Luini A; Intra M; Veronesi P; Mazzarol G; Pruneri G; Renne G; Torrisi R; Cardillo A; Cancello G; Goldhirsch A; Colleoni M
Breast Cancer Res Treat; 2009 Nov; 118(2):385-94. PubMed ID: 19562480
[TBL] [Abstract][Full Text] [Related]
14. Cyclin B is an immunohistochemical proliferation marker which can predict for breast cancer death in low-risk node negative breast cancer.
Koliadi A; Nilsson C; Holmqvist M; Holmberg L; de La Torre M; Wärnberg F; Fjällskog ML
Acta Oncol; 2010 Aug; 49(6):816-20. PubMed ID: 20307242
[TBL] [Abstract][Full Text] [Related]
15. [Prognostic molecular classification of breast cancers based on gene expression profiling].
Feng YM; Li XQ; Sun BC; Gao XC; Gu L; Niu Y; Hao XS
Zhonghua Zhong Liu Za Zhi; 2006 Dec; 28(12):900-6. PubMed ID: 17533740
[TBL] [Abstract][Full Text] [Related]
16. Prospective multicenter validation of the independent prognostic value of the mitotic activity index in lymph node-negative breast cancer patients younger than 55 years.
Baak JP; van Diest PJ; Voorhorst FJ; van der Wall E; Beex LV; Vermorken JB; Janssen EA
J Clin Oncol; 2005 Sep; 23(25):5993-6001. PubMed ID: 16135467
[TBL] [Abstract][Full Text] [Related]
17. Gene expression signature predicts recurrence in lung adenocarcinoma.
Larsen JE; Pavey SJ; Passmore LH; Bowman RV; Hayward NK; Fong KM
Clin Cancer Res; 2007 May; 13(10):2946-54. PubMed ID: 17504995
[TBL] [Abstract][Full Text] [Related]
18. The prognostic value of proliferation in lymph-node-negative breast cancer patients is age dependent.
Baak JP; van Diest PJ; Voorhorst FJ; van der Wall E; Beex LV; Vermorken JB; Janssen EA; Gudlaugsson E;
Eur J Cancer; 2007 Feb; 43(3):527-35. PubMed ID: 17110097
[TBL] [Abstract][Full Text] [Related]
19. Clinical utility of the 70-gene MammaPrint profile in a Japanese population.
Ishitobi M; Goranova TE; Komoike Y; Motomura K; Koyama H; Glas AM; van Lienen E; Inaji H; Van't Veer LJ; Kato K
Jpn J Clin Oncol; 2010 Jun; 40(6):508-12. PubMed ID: 20110242
[TBL] [Abstract][Full Text] [Related]
20. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients.
Györffy B; Lanczky A; Eklund AC; Denkert C; Budczies J; Li Q; Szallasi Z
Breast Cancer Res Treat; 2010 Oct; 123(3):725-31. PubMed ID: 20020197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
